Rivaroxaban and apixaban as an alternative treatment option to standard therapy (of LMWH) for cancer related VTE treatment.
Tab Title Description
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
- Rochester, Minnesota: 15-004382
Sponsor Protocol Number: 15-004382
About this study
To evaluate the efficacy of rivaroxaban and apixaban in treating malignancy associated VTE by comparing to the standard of care, low molecular weight heparin (LMWH) and compare safety profile (bleeding diathesis) of rivaroxaban and apixaban in patients with malignancy associated VTE and compare it to LMWH treatment.
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
All patients with cancer-associated DVT or PE enrolled into the Mayo Rochester Thrombophilia Clinic Direct Oral Anticoagulants Registry between March 1, 2013 and June 10, 2015 and treated with rivaroxaban, apixaban or LMWH.
- Diagnosed with an active malignancy at the time of starting DOA or LMWH.
- Anticoagulation managed by the Mayo Rochester Thrombophilia Clinic.
- Age 18 – 90 years
- Less than 3 months since starting the treatment (rivaroxaban, apixaban or LMWH).
- Unable to follow up either by mail or telephone at minimum 3 months’ time.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
|Mayo Clinic Location
Mayo Clinic principal investigator
Robert McBane, M.D.
Closed for enrollment
Publications are currently not available